pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Nurtec
drug · small molecule
save

rimegepant sulfate ODT

Marketedupdated 6mo ago
by $PFE PFIZER INC🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugNURTEC ODT40 co-mentions · 10 sources
  • tagApproval40 co-mentions · 10 sources
  • tagSmall Molecule20 co-mentions · 10 sources

Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.

targets

Calcitonin gene-related peptide type 1 receptor

all catalysts(10)

approval · 10
Feb 27, 2020
approval
$PFE28.06-1.44%
7y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 18, 2020
approval
$PFE28.06-1.44%
6y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
May 27, 2021
approval
$PFE28.06-1.44%
5y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 8, 2021
approval
$PFE28.06-1.44%
5y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 31, 2022
approval
$PFE28.06-1.44%
5y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Apr 11, 2022
approval
$PFE28.06-1.44%
5y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 12, 2024
approval
$PFE28.06-1.44%
2y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 21, 2025
approval
$PFE28.06-1.44%
2y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 1, 2025
approval
$PFE28.06-1.44%
1y ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 16, 2026
approval
$PFE28.06-1.44%
8mo ago
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
view all 10 catalysts →

Trials studying rimegepant sulfate ODT

  • —A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Koreanot yet recruitingn=3,000
  • phase2Comparison of Rimegepant and Placebo for Pain in IBScompletedn=24

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 25, 2033
~6.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Mar 25, 2039formulationUS 11083724
  • Feb 27, 2034compositionUS 8314117
  • Feb 25, 2033compositionUS 8759372

News(5)

  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 6d ago
  • Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
    Pfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.
    biospace · 15d ago
  • Pfizer flat in Q3 despite 32% growth for new and acquired products
    Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
    biospace · 15d ago
  • New guidelines on migraine prevention reflect increasing options for patients
    “There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.
    stat · 2mo ago
  • Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
    Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
    biopharma_dive · 2mo ago
brand
Nurtec
trade names
Nurtec odt, Vydura
generic
rimegepant sulfate
MOA
Calcitonin gene-related peptide type 1 receptor antagonist
indication
Rhinosinusitis
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?